drugset / Trial / NCT05084677

Toripalimab Combined With Concurrent Chemoradiotherapy in Cervical Cancer

NCT05084677 ↗

NaSingle-groupOpen-labelTreatment

Summary

To explore the efficacy and tolerance of adding toripalimab simultaneously and subsequently to concurrent platinum-based chemoradiotherapy in patients with locally advanced cervical cancer.

Timeline

Start
2021-01-01
Primary completion
2022-12-31
Completion
2024-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Toripalimab Monoclonal antibody 240 mg Intravenous

Indications